Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Health care utilization and mortality among elderly patients with myelodysplastic syndromes.

Lindquist KJ, Danese MD, Mikhael J, Knopf KB, Griffiths RI.

Ann Oncol. 2011 May;22(5):1181-8. doi: 10.1093/annonc/mdq552. Epub 2010 Nov 1.

2.

Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.

Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X.

Cancer. 2016 May 15;122(10):1598-607. doi: 10.1002/cncr.29945. Epub 2016 Mar 11.

3.

Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia.

Kako S, Nakasone H, Endo H, Sakamoto K, Ashizawa M, Sato M, Terasako K, Kikuchi M, Kimura S, Okuda S, Yamazaki R, Oshima K, Tanihara A, Nishida J, Usuki K, Kanda Y.

Hematol Oncol. 2012 Jun;30(2):82-8. doi: 10.1002/hon.1001. Epub 2011 Jun 21.

PMID:
21692099
4.

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.

Zandberg DP, Huang TY, Ke X, Baer MR, Gore SD, Smith SW, Davidoff AJ.

Haematologica. 2013 Apr;98(4):584-90. doi: 10.3324/haematol.2012.062547. Epub 2012 Nov 9.

5.

Myelodysplastic syndromes: incidence and survival in the United States.

Ma X, Does M, Raza A, Mayne ST.

Cancer. 2007 Apr 15;109(8):1536-42.

6.

Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.

Yabe M, Medeiros LJ, Tang G, Wang SA, P Patel K, Routbort M, Bhagat G, Bueso-Ramos CE, Jorgensen JL, Luthra R, Chen W, Muzzafar T, Kanagal-Shamanna R, Khoury JD, Daneshbod Y, Davanlou M, Li S, Young KH, Miranda RN.

Hum Pathol. 2016 Apr;50:109-17. doi: 10.1016/j.humpath.2015.11.010. Epub 2015 Dec 2.

PMID:
26997444
7.

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.

Tatarelli C, Piccioni AL, Maurillo L, Naso V, Battistini R, D'Andrea M, Criscuolo M, Nobile C, Villivà N, Mancini S, Neri B, Breccia M, Fenu S, Buccisano F, Voso MT, Latagliata R, Aloe Spiriti MA.

Ann Hematol. 2014 Aug;93(8):1413-20. doi: 10.1007/s00277-014-2053-9. Epub 2014 Mar 20.

PMID:
24647684
8.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Transfusion. 2010 Jan;50(1):190-9. doi: 10.1111/j.1537-2995.2009.02361.x. Epub 2009 Aug 28.

PMID:
19719471
9.

Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.

Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA.

Cancer. 2016 Apr 15;122(8):1209-15. doi: 10.1002/cncr.29913. Epub 2016 Feb 23.

10.

Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy.

Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM.

Leuk Lymphoma. 2014 May;55(5):1119-25. doi: 10.3109/10428194.2013.820286. Epub 2013 Aug 28.

11.

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.

Breccia M, Latagliata R, Cannella L, Carmosino I, Santopietro M, Loglisci G, Federico V, Alimena G.

Leuk Lymphoma. 2010 May;51(5):783-8. doi: 10.3109/10428191003682759.

PMID:
20302387
12.

Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008.

McQuilten ZK, Polizzotto MN, Wood EM, Sundararajan V.

Transfusion. 2013 Aug;53(8):1714-21. doi: 10.1111/trf.12054. Epub 2013 Jan 10.

PMID:
23305556
13.

Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis.

Kim KJ, Kwok SK, Park YJ, Kim WU, Cho CS.

Int J Rheum Dis. 2012 Feb;15(1):86-94. doi: 10.1111/j.1756-185X.2012.01704.x.

PMID:
22324951
14.

Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.

Craig BM, Rollison DE, List AF, Cogle CR.

Leuk Res. 2011 Nov;35(11):1453-6. doi: 10.1016/j.leukres.2011.07.028. Epub 2011 Aug 17.

15.

Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.

Ryblom H, Hast R, Hellström-Lindberg E, Winterling J, Johansson E.

Eur J Oncol Nurs. 2015 Apr;19(2):99-106. doi: 10.1016/j.ejon.2014.10.011. Epub 2014 Nov 5.

PMID:
25488465
16.

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):401-10. doi: 10.1016/j.clml.2014.03.001. Epub 2014 May 6.

17.

The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome.

Cordoba I, Gonzalez-Porras JR, Such E, Nomdedeu B, Luño E, de Paz R, Carbonell F, Vallespi T, Ardanaz M, Ramos F, Marco V, Bonanad S, Sanchez-Barba M, Costa D, Bernal T, Sanz GF, Cañizo MC.

Leuk Res. 2012 Mar;36(3):287-92. doi: 10.1016/j.leukres.2011.10.025. Epub 2011 Nov 30.

PMID:
22133642
18.

Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows.

Buckstein R, Jang K, Friedlich J, Zhang L, Reis M, Chesney A, Wells RA.

Leuk Res. 2009 Oct;33(10):1313-8. doi: 10.1016/j.leukres.2009.02.010. Epub 2009 Mar 17.

PMID:
19282029
19.

Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.

Dinmohamed AG, Visser O, van Norden Y, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M.

Eur J Cancer. 2014 Mar;50(5):1004-12. doi: 10.1016/j.ejca.2013.12.002. Epub 2013 Dec 31.

PMID:
24388662
20.

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR.

J Natl Cancer Inst. 2007 Feb 7;99(3):196-205.

PMID:
17284714

Supplemental Content

Support Center